Patent Infringement case: Delhi HC rules in favour of Natco Pharma
New Delhi: Natco Pharma has recently announced that the company has received a favourable verdict from Delhi High Court in a patent infringement case.A double bench of the High Court of Delhi has dismissed an appeal filed by FMC Corporation, FMC Singapore and FMC India, and has upheld prima facie the judgement of the single judge that the company's Chlorantraniliprole (CTPR) process does...
New Delhi: Natco Pharma has recently announced that the company has received a favourable verdict from Delhi High Court in a patent infringement case.
A double bench of the High Court of Delhi has dismissed an appeal filed by FMC Corporation, FMC Singapore and FMC India, and has upheld prima facie the judgement of the single judge that the company's Chlorantraniliprole (CTPR) process does not infringe FMC's Indian Patent 298645, the drug firm said in a regulatory filing.
CTPR is used across a wide range of crops for pest management.
Medical Dialogues had earlier reported that the US-based FMC Corporation had filed a suit against NATCO for a Process Patent # IN 298645 in the Delhi High Court.
The Patent IN 298645 covers a process to prepare CTPR, an insecticide, that is set to expire on December 6, 2025.
In 2021, Delhi High Court had upheld an interim injunction against the drug maker filed by FMC Corporation over Chlorantraniliprole (CTPR), an ingredient that goes into making insecticides.
Read also: Natco Pharma dragged to Delhi HC over alleged patent violation
FMC sells chlorantraniliprole in India under the trade name Rynaxapyr active, which is the primary ingredient in Coragen and Ferterra insecticides.
Coragen and Ferterra insecticides are approved for controlling pests on rice, sugarcane, vegetables, maize as well as other important crops. These insecticides and their patented active ingredients are well known by farmers and recognized for their favorable safety and environmental profile, which has earned them a green label from India's regulatory body.
Read also: Natco Pharma unveils first generic version of Pomalyst capsules in Australia
Natco Pharma Limited is a vertically integrated and R&D-focused pharmaceutical company engaged in developing, manufacturing, and marketing of finished dosage formulations ("FDF") and active pharmaceutical ingredients ("APIs"). The company focuses primarily on niche therapeutic areas and complex products. Natco market and distribute its products in over 40 countries.
Natco sells its FDF products in the United States, India, Europe, and the rest of the world ("RoW"). The company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd